Diovan HCT
Company: Novartis
Approval Status: Approved March 1998
Treatment for: second-line treatment of hypertension
Areas: Cardiology/Vascular Diseases; Endocrinology
Possible similar drugs: Diovan; Diovan
General Information
Other Useful Resources
Diovan HCT has been approved for second-line treatment of hypertension. Diovan HCT is a combination of an angiotensin II receptor blocker (ARB)--a first line treatment that lowers blood pressure with an overall incidence of side effects comparable to placebo--and a diuretic, which is commonly used with other therapies to provide additional blood pressure lowering.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
